<p>To ask the Secretary of State for Health and Social Care, whether it is his Department's policy to authorise novel pharmaceutical products, therapies or medical devices for first-time human clinical trials by the MHRA on a case-by-case basis without relying on a standardised complement of pre-clinical animal toxicity or efficacy data; and what steps he is taking to promote the use of non-animal pre-clinical data.</p>